We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

The Baycol scare

19 March 2003

While still hard to quantify, liabilities relating to the drug look increasingly unlikely to swamp the value of Bayer s healthcare unit. Baycol may be delaying the restructuring of the German conglomerate. But with luck it will shock Bayer into action.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)